Leadership
Our leadership team of experienced drug hunters is leveraging their experiences to shape our pioneering science and pipeline of first-in-class precision oncology medicines.

Andree Blaukat
CEO
Andree Blaukat
CEO
Andree is an executive with over 20 years of experience in oncology drug discovery and development, and the implementation of synthetic lethal concepts. Andree is passionate about good science, people, and precision medicine to turn cancer patients into survivors. He is responsible for building Tessellate Bio into a leading precision oncology company.
Previously, he was SVP and Head of Oncology Research at Merck KGaA, leading the global oncology and immune-oncology research teams to successfully discover and develop several drug candidates. Andree was a member of the team that took TEPMETKO® (tepotinib) from concept to commercialization and is a co-inventor of this medicine. During his tenure at Merck he also secured key strategic collaborations and licensing deals and established core focus areas in precision oncology, DNA damage response and antibody-drug conjugates.
Andree received a PhD in biochemistry from the Universities of Mainz & Darmstadt, Germany.


Katie Chapman
CSO
Katie Chapman
CSO
Katie is a skilled in vitro pharmacologist with a wealth of experience that spans over 15 years and a track record of delivery on diverse drug targets. Katie has a passion for enabling technologies which help in unlocking difficult to drug proteins.
She previously worked in senior scientist and drug discovery roles at large pharmaceutical companies including MSD and GSK, the CRO Domainex and in academia at Imperial College London.
Katie received a PhD at the University of Leeds, United Kingdom on the structure and function of GPCRs.


Lara Boyd
CBO
Lara Boyd
CBO
Lara has over a decade of experience in business development and corporate strategy, which includes establishing strategic partnerships, licensing deals, M&A and company formation.
Prior to joining Tessellate BIO, Lara held the position of VP, Head of Business Development and Corporate Strategy at F-star Therapeutics, a clinical-stage biopharma developing next generation bispecific antibodies. At F-star, Lara was responsible for driving strategic partnerships with biopharma, including Takeda, Johnson & Johnson, Merck KGaA, AstraZeneca, MSD and Denali Therapeutics, and was a core member of the deal team that oversaw the public listing of F-star in 2020 through a reverse merger with Spring Bank Pharmaceuticals, and more recently the acquisition of F-star by invoX Pharma in 2023.
Lara has also held business development roles at Cancer Research Technology (now Horizons) and Cancer Research UK, where she sat at the interface between academic research and industry and was responsible for translating promising academic research by establishing commercial partnerships.
Lara completed her PhD at the MRC Genome Damage and Stability Centre, investigating DNA Damage Repair pathways, and holds a degree in Biochemistry from Imperial College London.


David Hirst
Head of Chemistry
David Hirst
Head of Chemistry
David is a highly experienced medicinal chemist with a career spanning over 20 years within the bio-pharmaceutical industry.
Prior to joining Tessellate Bio, he held senior positions at MSD and GSK leading programs across a wide range of therapeutic area, target class and modality. He has an established track-record of success transcending the drug discovery process including the delivery of multiple clinical candidates.
David received a PhD in organic synthesis from the University of Nottingham, UK.


Joris Schuurmans
Head of Companion Diagnostics
Joris Schuurmans
Head of Companion Diagnostics
Joris has extensive experience gained from over 20 years of working in the biopharmaceutical and molecular diagnostics industry.
Joris is CEO of Delta Life Science, a company developing label-free, multiplex biosensing solutions. Before, he served as CEO at Cergentis, a genomics company based in the Netherlands, ahead of its acquisition by Solinas AG. He has also held other senior management roles at numerous companies including MDxHealth and Biocartis. Besides his position at Tessellate Bio, he is also Chief Development Officer at SkylineDx.
Joris received an MSc in Chemical Engineering from Delft University of Technology, The Netherlands.


Ana Maria Caballero Alias
Head of Finance
Ana Maria Caballero Alias
Head of Finance
Ana is a CIMA chartered management accountant. Highly motivated and driven by continuous improvement, she has held Finance and Controlling roles in several biotech companies, including Vernalis and Ascend, as well as at IQVIA.
Ana received her PhD in Biomaterials from Nottingham Trent University, United Kingdom and was a researcher at UCL and Cambridge University before moving into finance.


Lee Larcombe
Head of BioIT
Lee Larcombe
Head of BioIT
Lee is a computational biologist with extensive experience supporting data-driven R&D in both academia and industry.
Lee has a research track record in oncology and brings his specialist expertise in new target discovery, characterization, and (bio)therapeutic development, to lead the discovery bioinformatics activities for Tessellate Bio. He is also the founder and CEO of Apexomic, a discovery CRO providing expert data analytics for life science R&D and CEO and co-founder of Isoform Oncology, a company exploiting switching and alternative splicing for the development of new cancer biotherapeutics.
Lee received a PhD in Bioscience, Bioinformatics from Cranfield University, United Kingdom.

Board of Directors
Our Board of Directors have a track record of managing and building early-stage life science companies and fundraising.

Eliot Forster
Chair of the Board
Eliot Forster
Chair of the Board
Eliot has over 30 years of experience in the pharmaceuticals and biotechnology sectors. Previously, Eliot was CEO of clinical-stage F-star Therapeutics (NASDAQ:FSTX) until its acquisition by inovX Pharma Ltd in March 2023, and formerly CEO of Immunocore (NASDAQ:IMCR), CEO of Creabilis, and President and CEO of Solace Pharmaceuticals. Earlier in his career, he held senior management positions at Pfizer and GSK.
Elliot is CEO of Levicept Ltd. and is non-executive Chairperson of Avacta plc, Ochre Bi and Protalix Inc. He is an honorary visiting Professor of Molecular and Clinical Cancer Medicine at the University of Liverpool and honorary international visiting Professor at the University of Pavia. He is also a Board member of OSCHR (Office for Strategic Coordination of Health Research), and the National Genomics Board.
Eliot received a PhD in neurophysiology from the University of Liverpool and an MBA from Henley Business School.


Professor Claus Azzalin
Co-founder
Professor Claus Azzalin
Co-founder
Claus is a co-founder of Tessellate Bio and a group leader at Instituto de Medicina Molecular (iMM), Lisbon, Portugal and Professor at the University of Lisbon.
His research focuses on how telomeric long noncoding RNA (TERRA) supports telomere elongation in cancer cells, and the consequences of perturbing TERRA transcription and localization on telomere integrity and cellular physiology.
Previously he was an Assistant Professor at ETH Zürich, Switzerland. He served as a postdoctoral researcher at the Memorial Sloan-Kettering Cancer Centre, New York and at the Swiss Institute for Experimental Cancer Research.
He received his PhD from the Università degli Studi di Pavia, Italy.


Professor Hilda Pickett
Co-founder
Professor Hilda Pickett, PhD
Co-founder
Hilda is a co-founder of Tessellate Bio and is Head of the Telomere Length Regulation Unit at Children’s Medical Research Institute (CMRI), and Conjoint Professor at the University of Sydney.
In December 2012, she established the Telomere Length Regulation Group. Her lab’s research focuses on understanding the molecular mechanisms that underlie telomere length control, genomic stability and cellular immortality.
Previously she held a postdoctoral position with Cancer Research UK at St James’s University Hospital in Leeds, UK, before moving to Australia as a postdoctoral fellow in the Cancer Research Unit at CMRI.
Hilda received her PhD from the Department of Genetics at the University of Leicester, United Kingdom.


Andree Blaukat
CEO
Andree Blaukat
CEO
Andree is an executive with over 20 years of experience in oncology drug discovery and development, and the implementation of synthetic lethal concepts. Andree is passionate about good science, people, and precision medicine to turn cancer patients into survivors. He is responsible for building Tessellate Bio into a leading precision oncology company.
Previously, he was SVP and Head of Oncology Research at Merck KGaA, leading the global oncology and immune-oncology research teams to successfully discover and develop several drug candidates. Andree was a member of the team that took TEPMETKO® (tepotinib) from concept to commercialization and is a co-inventor of this medicine. During his tenure at Merck he also secured key strategic collaborations and licensing deals and established core focus areas in precision oncology, DNA damage response and antibody-drug conjugates.
Andree received a PhD in biochemistry from the Universities of Mainz & Darmstadt, Germany.


Daniela Couto
BioGeneration Ventures
Daniela Couto
BioGeneration Ventures
Daniela is a General Partner at BGV.
She served as the managing director of BGV’s portfolio company Staten Biotechnology, where she led and executed on company strategy, including the collaboration with argenX and its partnership and buy-out option with Novo Nordisk.
Previously, Daniela served as CEO at Cell2B, a cell therapy company that she co-founded with IP and technology from Prof. Sangeeta Bhatia’s lab at the Broad Institute (MIT) for graft-versus-host disease and other immunological diseases.
She holds a PhD in BioEngineering from the Instituto Superior Técnico (IST-UTL) in collaboration with the Massachusetts Institute of Technology (MIT-Portugal Program).


Rogier Rooswinkel
Forbion
Rogier Rooswinkel
Forbion
Rogier is a General Partner at Forbion.
He is responsible for evaluating and structuring new investment opportunities across all disease areas with an emphasis on oncology. Rogier was closely involved in investments in Rigontec, Replimune, Enterprise, KaNDy and establishing the university spin-out Catalym.
He currently also serves as a board member for Amphista, Catalym, and as a board observer for Enterprise, Prilenia, and Escalier. Previously, he was a board director of Achilles (NASDAQ: ACHL) and an observer at Replimune (NASDAQ: REPL).
He holds a PhD from the University of Amsterdam for research he performed at the Netherlands Cancer Institute (NKI).
